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Abstract 
The patient is the centre of a web of relationships and the impact of his/her disease on family 
members and caregivers must be taken into account. The aim of this study was to identify the 
specific instruments that measure the impact of a dermatological disease on the quality of life 
(QoL) of family members, by performing a systematic search of the literature. Fifteen papers 
were identified, describing the creation and validation of nine instruments. Four of them 
concerned atopic dermatitis (Dermatitis Family Index, DFI; Parents’ Index QoL Atopic 
Dermatitis, PiQoL-AD; QoL in Primary Caregivers of children with Atopic Dermatitis, 
QPCAD; Childhood Atopic Dermatits Impact Scale, CADIS), two measured the impact of 
psoriasis in family members (Psoriasis Family Index, PFI; FamilyPso), one the impact of 
epidermolysis bullosa (Epidermolysis Bullosa Burden of Disease, EB-BoD), one of ichthyosis 
(Family Burden Ichthyosis, FBI), and one was generic for dermatological conditions (Family 
Dermatology Life Quality Index, FDLQI). The EADV quality of life taskforce recommends 
that  the impact of a skin disease on family and caregivers should be measured as part of any 
thorough evaluation of the burden of a disease. Guidelines are given to choose the most 
appropriate instruments. 
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Introduction 
Skin conditions may have an impact not only on the patient’s life, but also on the lives of 
family members and caregivers 1. Basra and Finlay proposed the concept of ‘the Greater 
Patient’ 2,3 to describe the group of people who are close to a patient, and whose lives are 
therefore also affected by the patient’s disease. The patient is at the centre of a web of 
relationships, which have to be taken into account when planning care.  This is particularly 
true when the patient is a child, for example with atopic dermatitis 4,5, where family members 
are burdened with time-consuming treatment regimens and dietary and household changes, as 
well as financial impact. However, the family members of adult patients with chronic skin 
disease may also experience practical and psychosocial consequences.  Finlay 6 defined three 
dimensions of skin disease burden: 'now', 'long term' and 'family', the first two concerning the 
patient, while the third dimension is the burden on the partner, family members and 
caregivers. In the last decade, there has been growing interest in this ‘third dimension’, 
however, the physical, psychosocial and economic impact of skin conditions on informal 
caregivers is still often unrecognised or underestimated.  Only a few specific instruments have 
been created to measure this impact. 
The aim of this study was to identify and describe the instruments that measure the impact of 
a patient having a skin disease on the quality of life (QoL) of family members, by 
systematically searching the literature.  On behalf of the European Academy of Dermatology 
and Venereology (EADV) Taskforce on Quality of Life, we evaluated these instruments using 
standard criteria, in order to provide guidelines for their use.  
 
Materials & methods 
A systematic search of the literature was undertaken to identify current instruments for 
assessing QoL in families and caregivers of patients with skin conditions.  
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Data source and search terms 
The MEDLINE database (using PubMed) was searched. The review covered the time period 
up to December 31st, 2016. The following structured search terms were developed using 
PubMed guidelines and MESH terms and were used in the database search: (dermatol* OR 
skin) AND (quality of life OR life quality) AND (caregiver OR carer OR family OR familial 
OR parent OR partner OR proxy). 
 
Selection procedure   
The titles and abstracts resulting from this search were screened for relevance. The full text 
articles were obtained for all titles/abstracts that appeared to meet the inclusion/exclusion 
criteria or where there was any uncertainty. The full text articles were then screened.  
The references given in the included articles were checked to identify other relevant articles.  
We only selected articles describing instruments that were designed specifically for 
dermatological conditions. 
 
Selection criteria  
The following articles were included: 1) articles that identified a technique (tool, instrument 
or questionnaire) for evaluating QoL and family reported outcomes in families, partners or 
caregiver of patients with skin disease; 2) articles that assessed the performance of these QoL 
instruments: 3) articles in the English language. 
The following articles were excluded: 1) articles related to general (not specific for 
dermatology) QoL measures designed to assess QoL of family, partner, caregiver or carer of 
patients; 2) articles describing only the use of specific measures designed to assess QoL of 
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family, partner, caregiver or carer of patients with skin conditions; 3) reviews on the topic; 4) 
articles describing instruments for which an English translation is not available. 
 
Evaluation criteria 
Instruments were analysed according to the criteria used by Both et al. 7 (Table 1). A score is 
given to the different properties that a measurement instrument should have, i.e., validity, 
interpretability, reliability, structure, responsiveness, item bias, cultural issues, respondent and 
administrative burden, and alternative forms. Each instrument was independently assessed by 
two authors (a different combination of authors for each instrument) and reviewed by FS. 
Discrepancies were discussed until an agreement was reached. 
Check of search completeness  
Any published new measure for family impact of skin disease will likely cite articles 
describing previous methods of measurement. Therefore articles that cited the original 
descriptions of the DFI, CDLQI , CADIS, PIQoL, QPCAD and PFI were identified on Google 
Scholar and checked to ensure that no other dermatology-specific measurement methods had 
been missed. 
 
Results 
The first PubMed search (December 2016) identified 862 papers. From these, we selected 60 
papers, by reviewing each title and abstract (see flowchart, Figure 1). Seven of the papers 
described general concepts, such as the impact of disease on family members 1,8, the Greater 
Patient concept 2,3, the three dimensions of skin disease burden (now, long term, and family)6, 
and the impact of atopic eczema on the family 4,5.  
Some articles concerned the measurement of the impact of a skin disease on family members, 
but did not use an instrument specifically designed for that purpose. For example, Misery et 
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al. 9 in a study of relatives of patients with atopic dermatitis used the SF-12, the short version 
of the SF-36, which is a generic instrument used as a population health measure, and the 
Epworth scale, a self-assessment questionnaire consisting of eight items which evaluate 
daytime sleepiness. In a study on the impact of haemangiomas in children on their parents 10a 
series of single questions were used but not a structured questionnaire.  The Hamilton Anxiety 
Scale and the Beck Depression Inventory have been used to assess depression and anxiety in 
the caregivers of pediatric dermatological patients 11. Family dynamics have been specifically 
studied in a study of children with atopic dermatitis 12, using the family APGAR instrument. 
To describe the impact of cutaneous T-cell lymphoma on family members and how they cope 
and adjust, Selman et al. 13 conducted semi-structured qualitative interviews and data were 
analysed thematically using the Family Adjustment and Adaptation Response model as an 
interpretative framework. Another study was excluded because although the QoL instrument 
was completed by parents, it actually evaluated the QoL of the child (PedQL-P 14: Pediatric 
Quality of Life Inventory Parent Versions). All six of these articles were excluded from 
further analysis for the reasons given above. 
Among the 47 remaining papers identified concerning use of dermatological QoL instruments 
in family and caregivers, one was a review of an instrument, 25 concerned the use of 
instruments, six described the validation of instruments in different languages, and two 
described instruments in languages other than English. Two more articles were included from 
a further search using the names of identified instruments, giving a total of 15 papers included 
in the review.  
From these papers, nine measures were identified, described in detail below. The analysis of 
these instruments, based on the criteria in Table 1, is given in Table 2. The main 
characteristics of the instruments are described in Table 3.   
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Of the 862 articles identified, 70 were in languages other than English: French 20 articles, 
German 14, Spanish 10 and articles in thirteen other languages.  We have reviewed the titles 
and, where relevant, abstracts of these articles.  No measurement instrument was described or 
used in these articles that had not already been identified from the English language 
publications. As a further check that no measures had been missed, articles identified by 
Google Scholar, that cited the original descriptions of the DFI (330 citations), CDLQI (93), 
CADIS (81), PIQoL-AD (77), QPCAD (20) and PFI (15) were reviewed. No additional 
dermatology specific measurement methods were identified from this review. 
 
Family Dermatology Life Quality Index (FDLQI) 
The FDLQI 15,16 is a dermatology-speciﬁc instrument which measures the adverse impact on 
the health-related QoLof family members of patients with skin disease. The questionnaire was 
based on information from semi-structured interviews with family members or partners of 
patients with a variety of skin diseases. A draft questionnaire of 19 items was created, which 
was tested for face and content validity, and 10 final items were selected. Italian 17, Persian 18 
and Ukranian 19 versions have been published. Other articles have described the use of the 
FDLQI 20-25. 
 
Dermatitis Family Index (DFI)  
The DFI questionnaire 26,27 is a disease-specific measure to assess the impact of atopic eczema 
on the QoL of the parents and other family members of affected children. An Arabic version 
28
 and a Ukrainian version 29 have been published. The DFI has been used in many studies 30-
45
. A review of the use of the instrument 46 showed that 26 studies correlated the DFI to other 
instruments, demonstrating its convergent validity. Internal consistency was demonstrated by 
three studies, with Cronbach’s alpha ranging from 0.85 to 0.90, and test-retest reliability by 
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one study. Fifteen studies demonstrated that DFI scores change in response to changes in the 
clinical condition of the affected child, thus confirming sensitivity to change. The DFI has 
been translated from English into 17 languages. Some studies used modified versions of the 
DFI 47-49.  
 
The Parents’ Index of Quality of Life in Atopic Dermatitis (PIQoL-AD) 
The PIQoL-AD 50,51 aims to give information on the impact, caused by childhood atopic 
dermatitis, on the QoL of the caregiver of affected children, aged 8 years or younger. The 
instrument was developed in several different countries simultaneously, starting from 
qualitative interviews. Rasch analysis was applied and items were removed from the initial 
45-item draft of the instrument in order to minimise misfit and redundancy and to ensure the 
unidimensionality of the scale. A final version of 28 items was obtained.  A change of 2 to 3 
PIQoL-AD points over time could be considered meaningful. The instrument has only been 
used in a few studies 52,53. 
 
Measure of quality of life in primary caregivers of children with atopic dermatitis (QPCAD) 
The QPCAD 54 is a self-report questionnaire to evaluate the QoL in the past week of primary 
caregivers of a child with atopic dermatitis. The preliminary QPCAD was created using semi-
structured interviews and consisted of 85 items grouped into 7 domains. The number of items 
was reduced to 19 on the basis of their meaning, then to address the floor effect, and finally 
using factor analysis. This instrument has only been used in the Japanese version. A short 
version is available 55. 
 
Childhood Atopic Dermatitis Impact Scale (CADIS) 
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The CADIS 56,57 measures the effects of atopic dermatitis on the QoL of affected children 
younger than six years and their families. A prototype 62-item instrument was developed 
from a conceptual framework based on data from a literature review and from directed focus 
sessions with experts and parents. Item reduction was performed using Rasch analysis and a 
shorter 45-item version obtained. The CADIS is responsive to clinical changes in atopic 
dermatitis, and correlates well with the SCORAD score.   
 
Psoriasis Family Index (PFI) 
The PFI 58-60 is a disease-specific instrument to measure the secondary impact of psoriasis on 
the health-related QoL of family members of psoriasis patients. The questions were based on 
information from interviews with relatives of people with psoriasis.  Following description of 
the first 15-item version, psychometric properties of the PFI were assessed using the Item 
Response Theory Rasch model, which suggested that no changes were required to the 
measure apart from the removal of one item. The final version consists of 14 questions. A 
Brazilian Portuguese version has been validated 61. 
 
FamilyPso 
The FamilyPso 62 is a questionnaire measuring the impact of psoriasis on partners or family. It 
was developed on the basis of a literature research and qualitative interviews with family 
members. It is possible to calculate a total score, which has high reliability. It has good 
convergent validity, being strongly correlated to the FDLQI (r=0.77). In comparison with the 
PFI-14, the FamilyPso has a greater focus on the emotional aspects of living with affected 
family members.   
 
Epidermolysis Bullosa Burden of Disease (EB-BoD) 
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The EB-BoD is a disease specific questionnaire assessing the burden on families of children 
with epidermolysis bullosa (EB) 63. It consists of 20 items. The questionnaire showed high 
internal consistency, with Cronbach´s alpha=0.90, and the intraclass correlation coefficient 
was 0.97. The EB-BoD score correlated with the mental scale of the SF-12, showing 
convergent validity, and EB-BoD was able to discriminate among the different clinical 
subtypes of EB. Sensitivity to change was not tested.  
 
Family Burden Ichthyosis (FBI) 
The FBI 64 is a questionnaire designed to specifically measure the burden on families of 
patients affected by ichthyosis. It correlates with the mental scale of the SF-12, showing 
convergent validity. The five dimensions of the FBI were significantly correlated with the 
severity score. The questionnaire was created in French and translated into English according 
to good practice, including cross-cultural validation.  
 
Other questionnaires 
A 22-item German questionnaire for parents of children with atopic eczema (Fragebogen für 
Eltern von Neurodermitis kranken Kindern; FEN) has been developed 65 and used 66. The 
FEN includes four subscales: “aggressive behaviours towards scratching” (8 items), 
“protective behaviour” (7 items), “control of scratching” (4 items), and “negative experiences 
with the treatment” (3 items). High total scores represent high parental strain resulting from 
atopic dermatitis.  
“Fragebogen zur Lebensqualität von Eltern neurodermitiskranker Kinder” (Quality of life in 
parents of children with atopic dermatitis) 67, is another German instrument, used by von 
Rüden et al 68 and used in another study, with the name of “QoL in Parents of Children 
with Atopic Dermatitis” (PQoL-AD) 69.  It consists of 26 items, which can be divided by 
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factor analysis into five interpretable subscales: psychosomatic well-being, effects on social 
life, confidence in medical treatment, emotional coping, and acceptance of the disease. 
Convergent validity has been tested. The questionnaire is able to highlight differences 
between parents of children with varying degrees of disease severity, which is a prime 
indicator of clinical relevance. The questionnaire has shown high intraclass coefficients for 
test-retest reliability. The reliability of the subscales was medium to high, based on a 
Cronbach's alpha of between 0.57 and 0.90. The intercorrelations of the dimensions are 
moderate (0.20-0.63), which suggests that each dimension gives independent information on 
the various aspects of QoL. 
  
 
Discussion 
There is an increasing interest in the impact of skin conditions on family members and 
caregivers of patients. New instruments have been created to assess this often hidden aspect 
of the burden of skin disease. On reviewing the literature to identify the measurement 
instruments that are currently available, we found nine main instruments. Four of these were 
designed for use in atopic dermatitis. As this disease generally affects children, who need to 
be taken care of, the burden that atopic dermatitis has on caregivers was an obvious first area 
on which research was focussed. The first questionnaire on family burden was the DFI, which 
has since become the most used and most widely translated. Over the same period, two 
German questionnaires (FEN and PQoL-AD) were created, then the PiQoL-AD, followed by 
the QPCAD and the CADIS. These last instruments have been used in very few studies. In 
general, the validity and reliability of the instruments concerning atopic dermatitis have been 
appropriately addressed, however some of their properties still need to be evaluated. In 
particular no information been published concerning interpretation of scores for any of these 
instruments, for example score banding descriptors or minimal clinically important score 
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difference to aid interpretability of score change. Such information is particularly important to 
make measures useful clinically by giving meaning to scores and to their change over time. 
Rasch analysis, for item selection and to test unidimensionality, was performed in the 
development of three measures, the PiQoL-AD, the CADIS, and the PFI-14: in the 
development of the other questionnaires items were selected by factor analysis. Cultural 
aspects were generally not addressed, though they should be considered, especially since the 
instruments were created in and used in different countries. For example the QPCAD was 
created in Japan, and the authors emphasized 54 that some cultural differences are present 
compared to instruments such as the DFI. Items related to financial demands and leisure were 
excluded from the final version of the QPCAD, since in Japan it is taken for granted that 
parents will make sacrifices for their children, and medical expenses are covered by national 
health insurance.  As a further reassurance that this review has not missed any relevant 
dermatology-specific measurement methods, two systematic reviews did not identify any 
other methods. 39,70 
Although the concept of “family” is apparently self-evident, in reality it is difficult to define 
and the concept differs between different cultures and has also been changing with time 1. The 
measures identified in this study were all designed to measure the impact “of having someone 
in the family with a skin condition” on specific individuals.  None of the measures were 
designed to assess the overall burden on the family unit (the total Greater Patient), though the 
names of the measures may be wrongly interpreted as suggesting this.  There is also a 
difference in the meaning of “caregiver” and “family member”: a family member might or 
might not also be a caregiver, and a caregiver might or might not also be a family member. 
Even though a sick child necessarily involves the lives of people close to the child, the 
concept of the Greater Patient 2,3 can be applied to all patients, since every human being is the 
centre of a web of relationships. Based on this assumption, Finlay et al. created the FDLQI, an 
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instrument which measures the adverse impact on the health-related QoL of family members 
of patients with any skin disease. The advantage of a dermatology-specific instrument is that 
it may be used in all dermatological conditions, and it allows comparisons among skin 
diseases, though to compare the impact on family members of a skin disease with a non-skin 
disease a generic measure that can be used across all of medicine, such as FROM-16 71, would 
need to be used.   
So far, the FDLQI has been used in family members of patients with psoriasis 23,25, vitiligo 24, 
epidermolysis bullosa 17, leg ulcers 22, atopic dermatitis 20  and to measure the effect of 
cosmetic camouflage 21.  Validity, reliability, and responsiveness of the FDLQI have been 
extensively studied. It can be completed very quickly, since it has only ten items, and it has 
been translated into several languages. However, score descriptor categories and meaning of 
score change have still to be defined.  
More recently, in order to gain more information on the impact of a specific skin condition on 
family and caregivers, disease-specific instruments have been developed. These include the 
PFI and the FamilyPso for psoriasis, the EB-BoD for epidermolysis bullosa, and the FBI for 
ichthyosis. Up to now, they have been rarely used, and many of their properties still need to 
be evaluated. However, they may potentially be useful to detect the specific impairment due 
to a particular disease, and so it is important to be aware of their existence. Family member 
QoL instruments designed and validated for use specifically in one disease should not be used 
in a different skin disease, as the impact of different diseases may have subtle differences 8. 
This paper follows three papers published by the EADV Taskforce on Quality of Life: the 
first concerned measurement instruments in adult patients with skin disease 72,  the second 
concerned the measurement of health-related QoL in children with skin disease 73, and the 
third described the potential benefits of measuring QoL in routine clinical practice 74.  One 
aim of the Taskforce is to outline principles for the measurement of health-related QoL in 
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dermatological research and practice. In the first paper 69, the Taskforce described the 
psychometric properties which an instrument should meet to be used in clinical research or 
practice, i.e., scale structure, reliability, validity and responsiveness.  Family QoL instruments 
should obviously also meet the same criteria. We have identified satisfactory aspects of 
validation of  of some generic and disease-specific instruments, but for most instruments 
various aspects of validation still need to be studied.  
We did not identify any information concerning the use of these measures in routine clinical 
practice.  However it is potentially possible that the use of such measures in certain clinical 
situations might be of benefit, as has been suggested concerning the routine use of QoL 
measures designed for patients 74. 
 
Conclusions 
This review has identified nine instruments that are designed to measure the impact on the 
lives of family members, partners and carers of having someone in the family with a skin 
disease.  The ability to measure this largely hidden impact is the first step in being able to 
more fully understand the impact.  This has the potential to encourage the development of 
strategies to address these issues and support those affected, and to measure the effectiveness 
of atempts at intervention. 
 
EADV Task Force on Quality of Life recommendations 
The EADV Taskforce on Quality of Life makes the following recommendations concerning 
the instruments measuring health-related QoL in family and caregivers of patients with skin 
disease: 
1. The measurement of the impact of a skin disease on family and caregivers should be 
included in a thorough evaluation of the burden of the disease. 
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2. To choose the most appropriate instrument, it is important first to have clarity in the 
aim of a study. If the aim is to have details on the impact of a particular skin disease, a 
disease-specific questionnaire should be chosen. On the other hand, use of a generic 
instrument will allow comparison of the impact of a particular disease with the impact 
of other diseases. 
3. Before using an instrument, it is important to verify if a validated translated version 
exists for the population to be studied. Otherwise, the study may be an opportunity to 
validate a new translated version, following standard validated translation guidelines.  
4.  Before using an instrument for research, it is important to verify whether properties 
such as scale structure, validity, reliability, and responsiveness have been evaluated. If 
not, consider whether any of these properties could be evaluated in the proposed new 
study. 
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Table 1. Evaluation table for the properties of the measurement instruments  
Characteristics Definitions Grades and criteria 
 
 
Validity 
1. Conceptual 
 
 
2. Construct 
 
3. Convergent 
 
 
Does the tool measure what it is 
supposed to measure? 
Are the relevant domains captured? 
Does tool confirm hypothesized 
difference (e.g., diagnosis, clinical 
disease severity..) 
Does the tool relate to other tools 
measuring the same construct? 
1. 
A: well balanced 
objective and 
subjective domains 
B: more focused on 
objective or subjective 
domains 
C: missing important 
quality of life domains 
2. 
A: >75% of results 
are in accordance 
with specific 
hypothesis 
B: <75% of results 
are in accordance 
with specific 
hypotheses 
C: no information 
3. 
A: correlation >0.70 
B: correlation <0.70 
C: no information 
 
Interpretability 
1. Norms 
 
 
 
2. Categorization 
 
3. MCID (Minimal 
Clinically 
Important 
Difference) 
 
 
Are there standard comparative data 
from the general population and/or 
dermatology patients published and/or 
available? 
Are there categories of the obtained 
score available? 
Has the minimal change that is relevant 
to patients been reported? 
 
 
1. 
A: general and 
dermatology patients 
B: general or 
dermatology patients 
C: general nor 
dermatology patients 
 
2. 
A: using anchor or 
banding 
techniques 
B: using 
distribution based 
techniques 
C: not reported 
 
3. 
A: MCID is known 
in heterogeneous 
sample 
B: MCID is known 
in limited sample 
C: not reported 
 
Reliability 
1. Internal consistency 
 
 
 
 
 
2. Retest-reliability 
(ICC= intraclass 
correlation 
coefficient) 
 
 
Does the tool provide a consistent 
answer? 
The extent to which items in a 
(sub)scale are intercorrelated, thus 
measuring the same construct 
(Cronbach’s α)? 
Does a repeated administration of the 
tool within a reasonable period result in 
a similar outcome? 
 
1. 
A: 0.95>Cronbach’s 
α>0.70 
B: Cronbach’s α <0.7 
or >0.95 
C: Cronbach’s α not 
reported 
2. 
A: k or ICC>0.7 
B: k or ICC<0.7 or 
correlation 
coefficients >0.7 
C: k or ICC not 
reported or 
correlation 
coefficient < 0.7 
 
 
Structure Have the domains and/or summary 
score of the tool been confirmed?  
A: item response theory 
B: factor analysis 
C: no factor analysis or item response theory 
 
Responsiveness Is the tool sensitive to detect changes 
over time or due to therapy using 
patient centered and/or clinical criteria?  
A: strong 
B: moderate or conflicting evidence 
C: absent, weak, or solely based on statistical evidence 
 
Item bias Do the items of the tool function 
similar across external factors such as 
age, gender, and diagnosis? 
A: strong 
B: moderate or conflicting evidence 
C: absent or weak 
 
Cultural issues 
1. Translations 
 
2. Cultural 
equivalence 
 
 
Has the tool been translated using 
guidelines? 
Has the tool been analysed in a cultural 
equivalence study? 
1. 
A: always 
B: sometimes 
C: never, not reported 
2. 
A: always 
B: sometimes 
C: never 
 
Respondent burden Is the length and content acceptable to 
the patient? 
A: brief (<15 min) 
B: long or problems of acceptability 
C: long and problems of acceptability 
 
Administrative burden How easy is the tool to administer, 
score and interpret? 
A: simple 
B: moderate 
C: complex 
 
Alternative forms Is the tool available and tested for 
alternate forms of administration such 
as interviews in person or telephone, 
self-administration or computer-
assisted interviews.  
A: strong evidence 
B: moderate or conflicting evidence 
C: absent or weak evidence 
 
 
Table 2. Evaluation of the family quality of life questionnaires according to the guidelines given in Table 1.  
 
Family 
Dermatology 
Life Quality 
Index 
(FDLQI) 
Dermatitis 
Family Index 
(DFI) 
Parents’ 
Index Qol 
Atopic 
Dermatitis 
(PiQoL-AD) 
 
QoL in 
primary 
caregivers of 
children with 
atopic 
dermatitis 
(QPCAD) 
Childhood 
Atopic 
Dermatitis 
Impact Scale 
(CADIS) 
Psoriasis 
Family 
Index (PFI) 
FamilyPso Epidermolysis 
Bullosa Burden 
of Disease (EB-
BoD) 
Family  
Burden 
Ichthyosis 
(FBI) 
 
Validity 
         
Conceptual A A B B A A B A A 
Construct A A/B A B A A C B B 
Convergent B A B B B C A/B B B 
 
         
Interpretability 
         
Norms C C C C C C C C C 
Categorization C B C C C C C C C 
MCID C C A C C C C C C 
 
         
Reliability 
         
Internal consistency A A A A/B A A A A A 
Retest reliability A A A A A A C A C 
 
         
Structure B C A B A A B B C 
Responsiveness A A A B A C C C C 
Item bias C C A C C A C C C 
 
         
Cultural issues 
         
Translations A A A C B B C B B 
Cultural equivalence C B C C C C C C C 
 
         
Respondent burden A A A A B A A B B 
Administrative burden A A A B B A A B B 
Alternative forms C C C B C C C C C 
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Table 3. Characteristics of the family quality of life questionnaires.  
 
Family 
Dermatology 
Life Quality 
Index 
(FDLQI) 
Dermatitis 
Family Index 
(DFI) 
Parents’ 
Index Qol 
Atopic 
Dermatitis 
(PiQoL-AD) 
 
QoL in 
primary 
caregivers of 
children with 
atopic 
dermatitis 
(QPCAD) 
Childhood 
Atopic 
Dermatitis 
Impact Scale 
(CADIS) 
Psoriasis 
Family Index 
(PFI) 
FamilyPso Epidermolysis 
Bullosa Burden 
of Disease (EB-
BoD) 
Family  
Burden 
Ichthyosis 
(FBI) 
 
References 15,16 
 
26,27
 
50,51
 
54
 
56,57
 
58-60
 
62
 
63
 
64
 
Condition All 
dermatological 
 
Atopic 
dermatitis 
Atopic 
dermatitis 
Atopic 
dermatitis 
Atopic 
dermatitis 
Psoriasis Psoriasis Epidermolysis 
Bullosa 
Ichthyosis 
Country UK 
 
UK UK, The 
Netherlands, 
Germany, 
Italy, Spain, 
France, US, 
Switzerland 
Japan US UK Germany France France 
Number of items 10 
 
10 28 19 45 14 15 20 25 
Possible answers 
 
4-point scale: 
not at all⁄not 
applicable, a 
little, quite a 
lot, very much. 
(0-3) 
4-point scale: 
not at all, a 
little, a lot, 
very much. 
(0-3) 
Not reported 5-point scale, 
from “none” 
to “extremely. 
(0-4) 
5-point scale, 
from “never” 
to “all the 
time”.  
(0-4) 
4-point scale: 
not at all, a 
little, a lot, 
very much. 
(0-3) 
5-point 
scale: 
not true, 
somewhat 
true, 
moderately 
true, quite 
true, very 
true. 
(0-4) 
 
7-point scale: 
always, very 
often, often, 
sometimes, 
rarely, never, 
not applicable. 
4-point 
scale: 
definitely 
yes, 
maybe, 
definitely 
not, I don’t 
know.  
Domains Emotional and 
physical 
wellbeing, 
relationships, 
social life, 
leisure 
activities, 
burden of care, 
Housework, 
food 
preparation 
and feeding, 
sleep, family 
leisure 
activities, time 
spent on 
Needs that can 
be influenced 
by a child 
having atopic 
dermatitis 
(e.g., need for 
child to have a 
safe and 
Exhaustion (7 
items), worry 
about atopic 
dermatitis (6 
items), family 
cooperation (3 
items), and 
achievement 
Five domains, 
three of whom 
refer to the 
impact on the 
family: family 
and social 
function, 
sleep, and 
Feelings of 
embarrassmen
t, frustration, 
worry about 
the reaction of 
other people, 
worry about 
their future, 
Emotional 
impact of the 
disease 
(emotional 
domain, 
ED), impact 
on daily 
activities 
Family life (7 
questions), 
child’s life (3), 
disease and 
treatment (5), 
and economic 
and social 
impact (5).  
Pain, daily 
life, 
familial 
and 
personal 
relationshi
ps, work 
and 
 20 
impact on 
job⁄study, 
housework and 
expenditure. 
shopping for 
the family, 
expenditure, 
tiredness, 
emotional 
distress, 
relationships 
between the 
main carer and 
partner or 
between the 
main carer and 
other children 
and helping 
with 
treatment. 
successful 
future, need 
for rest and 
relaxation, 
need for self-
respect, need 
for 
independence)
. 
(3 items). emotions.  relationships, 
housework 
due to 
psoriasis and 
to treatment, 
time spent on 
treatment, 
social life, 
sporting 
activities, 
leisure 
activities, type 
of clothes, 
routine 
shopping and 
sleep.   
and work or 
school and 
treatment 
characteristi
cs (social 
domain, 
SD), and 
influence on 
leisure 
activities 
and personal 
relationships 
(leisure 
domain, 
LD). 
psychologi
cal impact. 
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